Literature DB >> 17391173

Raised alanine transaminase and decreased adiponectin are features of the metabolic syndrome in patients with type 2 diabetes.

Ingrid J Hickman1, Jonathan P Whitehead, Johannes B Prins, Graeme A Macdonald.   

Abstract

AIM: The aim of the study was to investigate the relationship between the metabolic syndrome (MS), adiponectin and abnormal liver enzymes in patients with type 2 diabetes.
METHODS: Fasting serum was collected from 189 patients with type 2 diabetes, adiponectin was measure using radioimmunoassay and features of the MS were assessed.
RESULTS: Mean ALT was significantly higher in patients with the MS and higher ALT was associated with lower adiponectin levels. As the number of features of MS increased, ALT increased and adiponectin decreased independent of glycaemic control.
CONCLUSION: Hypoadiponectinemia and the MS may be linked with liver injury in patients with type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17391173     DOI: 10.1111/j.1463-1326.2006.00604.x

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  3 in total

1.  Metabolic syndrome is linked to a mild elevation in liver aminotransferases in diabetic patients with undetectable non-alcoholic fatty liver disease by ultrasound.

Authors:  Alireza Esteghamati; Arsia Jamali; Omid Khalilzadeh; Sina Noshad; Mohammad Khalili; Ali Zandieh; Afsaneh Morteza; Manouchehr Nakhjavani
Journal:  Diabetol Metab Syndr       Date:  2010-11-03       Impact factor: 3.320

2.  Capsanthin Inhibits both Adipogenesis in 3T3-L1 Preadipocytes and Weight Gain in High-Fat Diet-Induced Obese Mice.

Authors:  Sung Jun Jo; Jeung Won Kim; Hye Ok Choi; Jung Hwan Kim; Hyung Joong Kim; Sun Hee Woo; Byung Hoon Han
Journal:  Biomol Ther (Seoul)       Date:  2017-05-01       Impact factor: 4.634

3.  Changes in serum adiponectin concentrations in critical illness: a preliminary investigation.

Authors:  Bala Venkatesh; Ingrid Hickman; Janelle Nisbet; Jeremy Cohen; John Prins
Journal:  Crit Care       Date:  2009-07-02       Impact factor: 9.097

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.